Glucose-induced regulation of novel iron transporters in vascular endothelial cell dysfunction

Free Radical Research

Volumn 39, Issue 11, 2005, Pages 1203-1210

  Khan, Zia A ^a,b   Farhangkhoee, Hana ^a   Barbin, Yousef P ^a   Adams, Paul C ^a   Chakrabarti, Subrata ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Diabetes; Iron; Oxidative stress; Vasculopathy

Indexed keywords

FERROPORTIN 1; GLUCOSE; IRON; IRON CHELATING AGENT; MESSENGER RNA; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; TRANSFERRIN RECEPTOR;

ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DATA ANALYSIS; ENDOTHELIUM CELL; EXPOSURE; GENE EXPRESSION; HUMAN; HUMAN CELL; MEASUREMENT; OXIDATIVE STRESS; PROTEIN EXPRESSION; REGULATORY MECHANISM; UPREGULATION; VASCULAR ENDOTHELIUM;

BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CATION TRANSPORT PROTEINS; CELLS, CULTURED; DNA, COMPLEMENTARY; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IRON; IRON-BINDING PROTEINS; MODELS, BIOLOGICAL; OXIDATIVE STRESS; RECEPTORS, TRANSFERRIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; UP-REGULATION;

EID: 27744490839     PISSN: 10715762     EISSN: 10292470     Source Type: Journal    
DOI: 10.1080/10715760500143254     Document Type: Article

References (37)

1. Aleksandrovski YA. Molecular mechanisms of diabetic complications. Biochemistry (Mosc) 1998;63:1249-1257.
2. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579-2588.
3. Khan ZA, Chakrabarti S. Endothelins in chronic diabetic complications. Can J Physiol Pharmacol 2003;81:622-634.
4. Chakrabarti S, Khan ZA, Cukiernik M, Fukuda G, Chen S, Mukherjee S. Alteration of endothelins: A common pathogenetic mechanism in chronic diabetic complications. Int J Exp Diabetes Res 2002;3:217-231.
5. Laight DW, Carrier MJ, Anggard EE. Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab Res Rev 1999;15:274-282.
6. Khan ZA, Cukiernik M, Gonder JR, Chakrabarti S. Oncofetal fibronectin in diabetic retinopathy. Investig Ophthalmol Vis Sci 2004;45:287-295.
7. Chen S, Apostolova MD, Cherian MG, Chakrabarti S. Interaction of endothelin-1 with vasoactive factors in mediating glucose-induced increased permeability in endothelial cells. Lab Investig 2000;80:1311-1321.
8. Xin X, Khan ZA, Chen S, Chakrabarti S. Extracellular signal-regulated kinase (ERK) in glucose-induced and endothelin-mediated fibronectin synthesis. Lab Investig 2004;84: 1451-1459.
9. Chen S, Mukherjee S, Chakraborty C, Chakrabarti S. High glucose-induced, endothelin-dependent fibronectin synthesis is mediated via NF-kappa B and AP-1. Am J Physiol Cell Physiol 2003;284:C263-C272.
10. Srinivasan S, Hatley ME, Bolick DT, Palmer LA, Edelstein D, Brownlee M, Hedrick CC. Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia 2004;47: 1727-1734.
11. Weidig P, McMaster D, Bayraktutan U. High glucose mediates pro-oxidant and antioxidant enzyme activities in coronary endothelial cells. Diabetes Obes Metab 2004;6:432-441.
12. Ogita H, Liao J. Endothelial function and oxidative stress. Endothelium 2004;11:123-132.
13. Farhangkhoee H, Khan ZA, Mukherjee S, Cukiernik M, Barbin YP, Karmazyn M, Chakrabarti S. Heme oxygenase in diabetes-induced oxidative stress in the heart. J Mol Cell Cardiol 2003;35:1439-1448.
14. Andrews NC. Metal transporters and disease. Curr Opin Chem Biol 2002;6:181-186.
15. Fleming MD, Trenor CC, Su MA, Foernzler D, Beier DR, Dietrich WF, Andrews NC. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat Genet 1997;16:383-386.
16. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997;388:482-488.
17. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters TJ, Farzaneh F, Hediger MA, Hentze MW, Simpson RJ. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000;5:299-309.
18. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, Law TC, Brugnara C, Lux SE, Pinkus GS, Pinkus IL, Kingsley PD, Palis J, Fleming MD, Andrews NC, Zon LI. Positional cloning of zebrafish ferroportin 1 identifies a conserved vertebrate iron exporter. Nature 2000;403:776-781.
19. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000;275:19906-19912.
20. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 2004;350:2383-2397.
21. Koo SW, Casper KA, Otto KB, Gira AK, Swerlick RA. Iron chelators inhibit VCAM-1 expression in human dermal microvascular endothelial cells. J Investig Dermatol 2003;120:871-879.
22. Khan ZA, Barbin YP, Cukiernik M, Adams PC, Chakrabarti S. Heme-oxygenase-mediated iron accumulation in the liver. Can J Physiol Pharmacol 2004;82:448-456.
23. McLean M, Bowman M, Clifton V, Smith R, Grossman AB. Expression of the heme oxygenase-carbon monoxide signalling system in human placenta. J Clin Endocrinol Metab 2000; 85:2345-2349.
24. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trmpisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256-1262.
25. Adams PC, Speechley M, Kertesz AE. Long-term survival analysis in hereditary hemochromatosis. Gastroenterology 1991;101:368-372.
26. Fargion S, Mandelli C, Piperno A, Cesana B, Fracanzani AL, Fraquelli M, Bianchi PA, Fiorelli G, Conte D. Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis. Hepatology 1992;15:655-659.
27. Niederau C, Fisher R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-1119.
28. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004;291:711-717.
29. Oberley LW. Free radicals and diabetes. Free Radic Biol Med 1988;5:113-124.
30. Wolff SP. Diabetes mellitus and free radicals: Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 1993;49: 642-652.
31. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among US adults. Diabetes Care 1999;22:1978-1983.
32. Heikkila RE, Cabbat FS. The prevention of alloxan-induced diabetes in mice by the iron-chelator detapac: Suggestion of a role for iron in the cytotoxic process. Experientia 1982; 38:378-379.
33. Hattori N, Schnell O, Bengel FM, Rihl J, Nekolla SG, Drzezga AE, Standl E, Schwaiger M. Deferoxamine improves coronary vascular responses to sympathetic stimulation in patients with type 1 diabetes mellitus. Eur J Nucl Med Mol Imaging 2002; 29:891-898.
34. Pieper GM, Siebeneich W. Diabetes-induced endothelial dysfunction is prevented by long-term treatment with the modified iron chelator, hydroxyethyl starch conjugated-deferoxamine. J Cardiovasc Pharmacol 1997;30:734-738.
35. Zacharski LR, Gerhard GS. Atherosclerosis: A manifestation of chronic iron toxicity? Vasc Med 2003;8:153-155.
36. Rossi E, McQuillan BM, Hung J, Thompson PL, Kuek C, Beilby JP. Serum ferritin and C282Y mutation of the hemochromatosis gene as predictors of asymptomatic carotid atherosclerosis in a community population. Stroke 2000;31: 3015-3020.
37. Roest M, van der Schouw YT, de Valk B, Marx JJ, Tempelman MJ, de Groot PG, Sixma JJ, Banga JD. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 1999;100:1268-1273.